Understanding how certain lung cancers with specific mutations respond to new treatments
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer
This study is looking at how certain lung cancers with specific gene mutations behave and how a new drug called IACS-10759 might help target those cancer cells better, with the hope of finding new treatment options for patients with these mutations.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10864047 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind lung cancers that have mutations in the SWI/SNF chromatin remodeling complex, particularly focusing on the ARID1A and SMARCA4 genes. By using a novel small molecule called IACS-10759, the study aims to explore how these mutant cancer cells can be targeted more effectively. The researchers will examine the metabolic changes in these cancer cells and how they respond to energy stress, which could lead to new treatment strategies. The ultimate goal is to provide evidence that could support future clinical trials for patients with these specific lung cancer mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer that have mutations in the SWI/SNF chromatin remodeling complex.
Not a fit: Patients with lung cancer who do not have mutations in the SWI/SNF complex may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with specific mutations in lung cancer.
How similar studies have performed: Other research has shown promising results in targeting metabolic vulnerabilities in cancer cells, suggesting that this approach could be effective.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Lissanu, Yonathan — University of Tx Md Anderson Can Ctr
- Study coordinator: Lissanu, Yonathan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.